In one paragraphArticle in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Marta UlaszewskaPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7TY, UK.ORCID 0000-0003-4288-2892 Ji MaVirology, Antiviral Drug & Vaccine Research Group, Laboratory of Molecular Vaccinology and Vaccine Discovery (MVVD), KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, 3000 Leuven, Belgium.
Susan J MorrisPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7TY, UK.ORCID 0009-0000-1813-0557 Sophie M Jegouic GoodallPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7TY, UK.ORCID 0000-0002-4584-814X Winnie KerstensVirology, Antiviral Drug & Vaccine Research Group, Translational Platform for Virus, Vaccine and Cancer Research (TPVC), KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0003-4933-6448 Hendrik Jan ThibautVirology, Antiviral Drug & Vaccine Research Group, Translational Platform for Virus, Vaccine and Cancer Research (TPVC), KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0001-5785-8276 Lotte CoelmontVirology, Antiviral Drug & Vaccine Research Group, Laboratory of Molecular Vaccinology and Vaccine Discovery (MVVD), KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-7888-4534 Kai DallmeierVirology, Antiviral Drug & Vaccine Research Group, Laboratory of Molecular Vaccinology and Vaccine Discovery (MVVD), KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, 3000 Leuven, Belgium.ORCID 0000-0002-8117-9166 Sarah C GilbertPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7TY, UK.ORCID 0000-0002-6823-9750 Barbara DemaPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7TY, UK.ORCID 0000-0002-1692-9987 Funding
European Union Horizon Europe Programme 101137459
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
adenoviral vectorChAdOx1efficacyflavivirusimmunogenicityvaccineyellow fever
Identifiers
PMID41893809
PMCPMC13030295
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390